Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy

Smith, F. H.; Gallagher, William M.; Fox, Edward P.; Stephens, R. B.; Rexhepaj, Elton; Petricoin, Emanuel F.; Liotta, Lance A.; Kennedy, M. John; Reynolds, John V.

doi:10.1097/01.sla.0000245577.68151.bd

Cited by 67 publications

(35 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They found that serum samples taken 24/48 h after treatment could predict the ultimate pathologic response with 87.5% sensitivity and 80% specificity based on a pattern of 14 differentially expressed proteins. They concluded that techniques, such as SELDI-TOF-MS, capable of simultaneously detecting multiple markers might be able to predict response at an individual level [67]. Numerous other researchers have applied this technique for biomarker identification in breast, ovarian, colon, liver and gastric cancers with promising results [10,15,26,68].…”

Section: Mass Spectrometrymentioning

confidence: 96%

“…Although it allows highthroughput analyses, its use in biomarkers discovery is limited due to low-resolution [66]. Smith and co-workers employed this approach to detect early-stage response to treatment (neoadjuvant radiochemotherapy) in 20 patients with rectal tumors [67]. They found that serum samples taken 24/48 h after treatment could predict the ultimate pathologic response with 87.5% sensitivity and 80% specificity based on a pattern of 14 differentially expressed proteins.…”

Section: Mass Spectrometrymentioning

confidence: 98%

See 1 more Smart Citation

Proteomic strategies and challenges in tumor metastasis research

Hudler

Gorsic

Komel

2010

Clin Exp Metastasis

View full text Add to dashboard Cite

The rapidly evolving field of proteomics offers new approaches to understanding the pathogenesis of cancer and metastatic disease. Although numerous tumor markers have been identified with different genomic methods in the past, most are either not specific or sensitive enough to be used in routine clinical setting. The rationale for proteomic profiling is based on the fact that proteins represent the dynamic state of the cells, reflecting pathophysiological changes in the disease more accurately than genomic and epigenetic alterations. Emerging proteomic techniques allow simultaneous assessment of a large number of proteins at one time. The study of protein profiles in complex systems, such as plasma, serum or tissues of cancer patients is likely to become valuable for monitoring the response of patients during treatment or for detecting recurrence of the disease.

show abstract

Section: Mass Spectrometrymentioning

confidence: 96%

Section: Mass Spectrometrymentioning

confidence: 98%

Proteomic strategies and challenges in tumor metastasis research

Hudler

Gorsic

Komel

2010

Clin Exp Metastasis

View full text Add to dashboard Cite

show abstract

“…Ainda através da análise do sangue pela técni-ca de SELDI, Smith e cols 16 obtiveram sucesso em identificar os pacientes que apresentaram uma resposta completa à terapia neoadjuvante com uma sensibilidade de 87%.…”

Section: Proteômica: a Nova Fronteira?unclassified

Biologia molecular do câncer colorretal: uma revolução silenciosa em andamento

Pinho

2008

Rev bras. colo-proctol.

View full text Add to dashboard Cite

RESUMO: Embora os estudos sobre biologia molecular permaneçam como a principal expectativa para o surgimento de novos conceitos e recursos para o tratamento do câncer colorretal, a ausência de resultados de real impacto do ponto de vista clínico ao longo dos últimos anos podem representar uma frustração para quem não esteja acompanhando de perto a evolução das pesquisas nesta área. Assim sendo, nosso objetivo no presente texto é apresentar uma breve revisão do caminho percorrido até o momento desde os trabalhos pioneiros sobre carcinogênese colorretal até as pesquisas mais recentes sobre proteômica, demonstrando assim o constante fluxo de grandes avanços os quais possibilitam uma previsão realista a curto ou médio prazo da disponibilização de recursos de amplo impacto, com potencial para alterar de forma relevante os resultados do tratamento desta importante doença.Descritores: Câncer colorretal; biologia molecular. Apesar de ser um tema relativamente complexo para aqueles que atuam na prática clínica, é um verdadeiro consenso a expectativa de que os estudos baseados em biologia molecular venham a oferecer os necessários avanços na compreensão da fisiopatologia, do diagnóstico e do tratamento do câncer. Talvez em decorrência desta expectativa, temos freqüentemente a frustrante sensação de que apesar do grande volume de pesquisas realizadas ao longo dos últimos anos, permanecemos ainda distantes da obtenção de resultados relevantes capazes de transformar estas esperanças em uma realidade para nossos pacientes. Trabalho realizado no Laboratório de Biologia Molecular e Disciplina de Clínica Cirúrgica doAssim sendo, é nosso objetivo nesta Seção demonstrar que embora os resultados não tenham ainda atingido nossa prática diária, importantes avanços permanecem ocorrendo, contribuindo para o esclarecimento gradual do complexo mosaico representado pelo processo de carcinogênese, o que certamente representará um grande impacto sobre a medicina do terceiro milênio. Para melhor demonstrar estes avanços, apresentaremos aqui uma breve revisão do caminho percorrido até o momento através dos estudos em biologia molecular aplicada ao câncer. Biologia molecular: uma potente ferramenta Ao contrário de outras linhas de estudos dedicadas ao esclarecimento dos aspectos oncológicos como a imunologia ou a microbiologia, a biologia molecular representa a aquisição de uma ampla e abrangente gama de ferramentas geradas a partir de um grande desenvolvimento biotecnológico, as quais nos permitem a identificação e manipulação das biomoléculas que os compõem. Assim sendo, trata-se na verdade do processo de entrada em um amplo uni-

show abstract

“…Smith et al analyzed sera taken before and during course of treatment from 20 patients with rectal cancer in relation to response according to the Mandard tumor regression grade (TRG). Although the "optimal" pretreatment model performed poorly, a 14-peptide classifier in serum taken 24-48-hours after treatment resulted in sensitivity of 88% and specificity of 80% [60]. Applying an alternative 3-grade scale for response, Hayashida et al constructed a 4-peptide signature from profiles of 27 patients with squamous cell esophageal cancer.…”

Section: Radiation and Chemoradiation Therapymentioning

confidence: 99%

“…Three eligible studies evaluated profiling in relation to pathological response to neoadjuvant 5-FU-based chemoradiation [60][61][62]. Smith et al analyzed sera taken before and during course of treatment from 20 patients with rectal cancer in relation to response according to the Mandard tumor regression grade (TRG).…”

Section: Radiation and Chemoradiation Therapymentioning

confidence: 99%

Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies

et al. 2014

View full text Add to dashboard Cite

Introduction. Treatment selection tools are needed to enhance the efficacy of targeted treatment in patients with solid malignancies. Providing a readout of aberrant signaling pathways and proteolytic events, mass spectrometry-based (MS-based) peptidomics enables identification of predictive biomarkers, whereas the serum or plasma peptidome may provide easily accessible signatures associated with response to treatment. In this systematic review, we evaluate MS-based peptide profiling in blood for prompt clinical implementation. Methods. PubMed and Embase were searched for studies using a syntax based on the following hierarchy: (a) bloodbased matrix-assisted or surface-enhanced laser desorption/ ionization time-of-flight MS peptide profiling (b) in patients with solid malignancies (c) prior to initiation of any treatment modality, (d) with availability of outcome data. Results. Thirty-eight studies were eligible for review; the majority were performed in patients with non-small cell lung

show abstract

Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy

Cited by 67 publications

References 44 publications

Proteomic strategies and challenges in tumor metastasis research

Proteomic strategies and challenges in tumor metastasis research

Biologia molecular do câncer colorretal: uma revolução silenciosa em andamento

Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies

Contact Info

Product

Resources

About